SYNC

Syncona reports annual results, capital pool and portfolio progress for 2026

Syncona reported annual results showing portfolio progress, capital deployment, valuation changes and a new investment policy focused on shareholder returns...

Syncona appoints Norman Crighton to the Board

Syncona has appointed Norman Crighton as a non-executive director, with committee roles and shareholder priorities outlined...

Syncona outlines £250m shareholder return plan and refined investment strategy

Syncona has announced a new set of proposals focused on returning £250 million to shareholders through future portfolio realisations and refining its investment strategy to maximise long-term value...

Syncona proposes investment policy change

Syncona Limited is revamping its investment strategy to enhance shareholder value amid challenging biotech market conditions. Explore their proposed policy changes and cash return options...

Syncona’s Beacon reports positive 6-month data from XLRP trial

Syncona Ltd's portfolio company, Beacon Therapeutics, reveals promising Phase II DAWN trial results for laru-zova, targeting X-linked retinitis pigmentosa (XLRP)...

Syncona launches Slingshot to advance early-stage biotech innovations

Syncona Ltd launches Slingshot Therapeutics, investing £12.5 million to advance academic innovations into biotech with a focus on inflammatory diseases...

Syncona appoints John Roche as an independent Non-Executive Director

Syncona Ltd (LON:SYNC), a leading life science investor focused on creating, building and scaling a portfolio of global leaders in life science, has announced the appointment of John Roche as..

Syncona portfolio company Beacon Therapeutics raises $170 million in a Series B financing

Syncona Ltd (LON:SYNC) commits $42.5 million to Beacon Therapeutics' $170 million Series B financing to advance treatments for blinding retinal diseases...

Syncona adds two new companies to its portfolio, iOnctura and Yellowstone Biosciences

Syncona Ltd (LON:SYNC) expands its life science portfolio with €30M in iOnctura and £16.5M in Yellowstone Biosciences, enhancing their oncology innovations...

Syncona quarterly update: Net assets and portfolio value increase, key milestones achieved by portfolio companies

Syncona Limited has issued its quarterly update, reporting an increase in net assets and a positive NAV per share return. The company's life science portfolio also saw significant growth. Read..

Syncona’s portfolio company, Freeline, releases positive data on gene therapy for Gaucher disease

Syncona Ltd notes further safety and enzyme activity data from its portfolio company, Freeline Therapeutics, on its gene therapy candidate for Gaucher disease...

Syncona portfolio company Autolus presents clinical data updates

Syncona Limited (LON:SYNC), a leading healthcare company focused on creating, building and scaling a portfolio of global leaders in life science, noted that its portfolio company, Autolus Therapeutics Plc (Nasdaq:..

Syncona portfolio company Beacon presents data from AGTC-501 trial

Syncona Ltd (LON:SYNC), a leading life science investor focused on creating, building and scaling a portfolio of global leaders in life science, notes that its portfolio company, Beacon Therapeutics, has..

Syncona portfolio company Anaveon to present updated clinical data

Syncona Limited (LON:SYNC), a leading healthcare company focused on creating, building and scaling a portfolio of global leaders in life science, has noted that its portfolio company, Anaveon, has announced..

Syncona Limited portfolio company Gyroscope Therapeutics update on proposed IPO

Syncona Ltd (LON:SYNC), a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life science, notes the announcement that its portfolio company, Gyroscope Therapeutics..

Syncona Limited portfolio company Achilles IPO to raise approximately $175.5 million

·   Achilles is focused on developing personalised T cell therapies for the treatment of solid tumours, specifically targeting neo-antigens ·   Achilles has announced the pricing of its initial public offering at a..

Syncona Ltd new £25.3m commitment in £61.0m expanded Series A financing for Quell Therapeutics

Syncona Ltd (LON:SYNC) has announced a £25.3 million new commitment in a £61.0 million expanded Series A financing for Quell Therapeutics. This is the largest amount of funding to date..

Syncona Appoint Virginia Holmes as Non-Executive Director

Syncona Ltd (LON:SYNC), a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life sciences, has announced the appointment of Virginia Holmes as a..

Syncona Limited freeline files registration statement for proposed IPO in the United States

Syncona Ltd (LON:SYNC), a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life science, has noted that its portfolio company, Freeline Therapeutics Holdings..

Syncona appoints Dr Kemal Malik as Non-Executive Director

Syncona Ltd (LON:SYNC), a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life sciences, has announced the appointment of Dr Kemal Malik as..

Search

Funds

SYNC

Syncona reports annual results, capital pool and portfolio progress for 2026

Syncona reported annual results showing portfolio progress, capital deployment, valuation changes and a new investment policy focused on shareholder returns...

Syncona appoints Norman Crighton to the Board

Syncona has appointed Norman Crighton as a non-executive director, with committee roles and shareholder priorities outlined...

Syncona outlines £250m shareholder return plan and refined investment strategy

Syncona has announced a new set of proposals focused on returning £250 million to shareholders through future portfolio realisations and refining its investment strategy to maximise long-term value...

Syncona proposes investment policy change

Syncona Limited is revamping its investment strategy to enhance shareholder value amid challenging biotech market conditions. Explore their proposed policy changes and cash return options...

Syncona’s Beacon reports positive 6-month data from XLRP trial

Syncona Ltd's portfolio company, Beacon Therapeutics, reveals promising Phase II DAWN trial results for laru-zova, targeting X-linked retinitis pigmentosa (XLRP)...

Syncona launches Slingshot to advance early-stage biotech innovations

Syncona Ltd launches Slingshot Therapeutics, investing £12.5 million to advance academic innovations into biotech with a focus on inflammatory diseases...

Syncona portfolio company Beacon Therapeutics raises $170 million in a Series B financing

Syncona Ltd (LON:SYNC) commits $42.5 million to Beacon Therapeutics' $170 million Series B financing to advance treatments for blinding retinal diseases...

Syncona adds two new companies to its portfolio, iOnctura and Yellowstone Biosciences

Syncona Ltd (LON:SYNC) expands its life science portfolio with €30M in iOnctura and £16.5M in Yellowstone Biosciences, enhancing their oncology innovations...

Syncona quarterly update: Net assets and portfolio value increase, key milestones achieved by portfolio companies

Syncona Limited has issued its quarterly update, reporting an increase in net assets and a positive NAV per share return. The company's life science portfolio also saw significant growth. Read more for details. #Syncona #quarterlyupdate #lifescienceinvestment..

Syncona’s portfolio company, Freeline, releases positive data on gene therapy for Gaucher disease

Syncona Ltd notes further safety and enzyme activity data from its portfolio company, Freeline Therapeutics, on its gene therapy candidate for Gaucher disease...
Search

Funds

SYNC

FTSE 100

Funds